There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Syros Pharmaceuticals (NASDAQ:SYRS) and Argenx Se (NASDAQ:ARGX) with bullish sentiments.
Syros Pharmaceuticals (SYRS)
Oppenheimer analyst Leah R. Cann maintained a Buy rating on Syros Pharmaceuticals today and set a price target of $26. The company’s shares opened today at $6.26, close to its 52-week low of $6.25.
Cann said:
“Syros’ 3Q18 loss per share was $0.47, in line with our estimate. Operating expenses of $16.7 million were slightly higher than our estimated $16.3 million, but were offset by higher interest income and slightly higher number of shares outstanding. There were no other remarkable variances in the quarter. Syros has a number of data presentations approaching, which we believe are very important for the company.”
According to TipRanks.com, Cann is a 3-star analyst with an average return of 1.7% and a 38.5% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
Currently, the analyst consensus on Syros Pharmaceuticals is a Moderate Buy with an average price target of $16.
See today’s analyst top recommended stocks >>
Argenx Se (ARGX)
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Argenx Se today. The company’s shares opened today at $87.05.
Archila noted:
“We view cusatuzumab’s (ARGX-110) data in acute myelogenous leukemia (AML) as very encouraging and while the study was small (n=12), we believe this program will be competitive to Roche/Abbvie’s Venclexta, which KOLs have indicated is the new bar for efficacy for AML patients ineligible for high intensity chemotherapy.”
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -10.5% and a 27.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $138.71, which is a 59.3% upside from current levels. In a report issued on October 19, Cowen & Co. also maintained a Buy rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
